<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1117">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04749563</url>
  </required_header>
  <id_info>
    <org_study_id>P1 IGC-AD1 BPSD</org_study_id>
    <nct_id>NCT04749563</nct_id>
  </id_info>
  <brief_title>Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease</brief_title>
  <official_title>A Phase I Randomized Placebo Controlled MAD Study to Evaluate Safety and Tolerability of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IGC Pharma LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>India Globalization Capital Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single center, randomized, placebo controlled multiple ascending dose study of IGC AD1 to&#xD;
      evaluate safety and tolerability in subjects with dementia due to Alzheimer's Disease (AD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I Multiple Ascending Dose (MAD) study to evaluate safety and tolerability of&#xD;
      IGC-AD1 in subjects with AD. Twelve subjects will be enrolled. Three different ascending&#xD;
      doses of the study product will be given: low, medium and high doses. Each dose will be given&#xD;
      for 2 weeks, followed by a washout period of 4 days. Given the vulnerability of the&#xD;
      population, a safety cohort of 3 patients (2 active, 1 placebo) will start every dose one day&#xD;
      ahead of the rest of the patients and will be followed for 24 hours for the development of&#xD;
      Adverse Events (AEs). Objective criteria will be set after the safety cohort is evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 11, 2021</start_date>
  <completion_date type="Actual">June 20, 2021</completion_date>
  <primary_completion_date type="Actual">June 20, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>3 dose escalation cohorts in same 12 subjects (5:1 randomization (active:placebo)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
    <masking_description>The study subjects will be blinded to the treatment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events in IGC-AD1 as compared to placebo [Safety and Tolerability]</measure>
    <time_frame>3 weeks</time_frame>
    <description>Evaluate safety and tolerability of IGC AD1 10 participants will be administered the investigational drug and two will be administered placebo. Incidence of treatment emergent adverse events will be assessed to determine safety and tolerability of IGC-AD1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy using Neuropsychiatric Inventory (NPI) scale</measure>
    <time_frame>3 weeks</time_frame>
    <description>Secondary Outcome: Comparison of the measurement of Neuropsychiatric Inventory (NPI) scale changes from baseline using the Suicide Severity Rating Scale (C-SSRS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Dementia of Alzheimer Type</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IGC AD1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IGC AD1 Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IGC AD1</intervention_name>
    <description>IGC AD1 oral Solution</description>
    <arm_group_label>Active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of IGC AD1 oral Solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient and/or study partner (relative) must provide a signed and dated Informed&#xD;
             Consent form prior to any study procedures which will be discussed with the Study&#xD;
             Coordinator.&#xD;
&#xD;
          2. Provision of a letter from the Neurologist/Psychiatrist/Internal Medicine Physician&#xD;
             certifying the diagnosis of Alzheimer's Dementia and patient's ability to consent. If&#xD;
             patient is unable to consent, only the legal guardian/tutor of the patient could&#xD;
             consent in his/her behalf. The guardian/tutor will be required to present the&#xD;
             pertinent legal documentation.&#xD;
&#xD;
          3. Must have a study partner who is able and willing to comply with all required study&#xD;
             procedures.&#xD;
&#xD;
          4. Patient should meet NIA-AA criteria for Alzheimer's disease, any stage.&#xD;
&#xD;
          5. At least 3 months evolution of behavioral symptoms at screening visit.&#xD;
&#xD;
          6. Negative drug screen, except for benzodiazepines if patient has been using them in&#xD;
             stable doses for at least 3 months before screening.&#xD;
&#xD;
          7. All medications used for behavioral symptoms should be in stable doses for at least 3&#xD;
             months before screening.&#xD;
&#xD;
          8. All medications used for other conditions besides behavioral symptoms should be at&#xD;
             stable doses for at least 30 days before screening.&#xD;
&#xD;
          9. Women must be postmenopausal (defined as cessation of menses for at least 1 year) or&#xD;
             surgically sterile (hysterectomy, oophorectomy or bilateral tubal ligation) at the&#xD;
             time of screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior adverse reaction to cannabinoids.&#xD;
&#xD;
          2. Prior contraindication or allergy to any component of study product (IGC-AD1):&#xD;
             melatonin, honey, curcumin, ethyl alcohol, vitamin-E TPGS, ascorbic acid, water,&#xD;
             tween-80, and rutin.&#xD;
&#xD;
          3. History of stroke, multiple sclerosis (MS), or epilepsy. History of gastrointestinal&#xD;
             dysfunction not related to Alzheimer's disease (e.g., inflammatory bowel disease or&#xD;
             gastrointestinal cancer)&#xD;
&#xD;
          4. Any clinically relevant neurological disorder capable of producing a dementia syndrome&#xD;
             including Parkinson's disease, stroke, vascular dementia, dementia with Lewy bodies,&#xD;
             frontotemporal dementia, and others.&#xD;
&#xD;
          5. Other possible causes of dementia as: infections of the CNS (e.g. HIV, syphilis) or&#xD;
             Creutzfeldt Jakob disease, subdural hematoma, communicating hydrocephalus, brain&#xD;
             tumors, drug intoxication, alcohol intoxication, thyroid disease, parathyroid disease,&#xD;
             and vitamin B12 or other deficiencies&#xD;
&#xD;
          6. Use of contraindicated medication (see section 6).&#xD;
&#xD;
          7. History of myocardial infarction, severe congestive heart failure, unstable angina,&#xD;
             significant valvular disease, or cardiomyopathy within 1 year of screening.&#xD;
&#xD;
          8. History of cardiac arrhythmias, second or third-degree AV block.&#xD;
&#xD;
          9. History of seizures, schizophrenia, or bipolar disorder.&#xD;
&#xD;
         10. Other condition or clinically important abnormality on vital signs, physical&#xD;
             examination, neurologic examination, laboratory results or electrocardiogram (ECG)&#xD;
             examination that could compromise the study efficacy interpretation or safety of the&#xD;
             subject.&#xD;
&#xD;
         11. Have participated in an investigational drug or device study within 30 days prior to&#xD;
             study start.&#xD;
&#xD;
         12. TCA or opioid use within 30 days before the enrollment.&#xD;
&#xD;
         13. History of alcohol and drug abuse within 2 years of screening.&#xD;
&#xD;
         14. Elevated liver enzymes (AST or ALT ≥3 times upper limit of normal, Total bilirubin≥1.5&#xD;
             times ULN or ALP≥1.5 times ULN).&#xD;
&#xD;
         15. Urine drug screen positive for drug use, except for benzodiazepines if patient was&#xD;
             using them previously and their dose had remained stable for at least 3 months before&#xD;
             screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>IGC Pharma INC</last_name>
    <role>Study Director</role>
    <affiliation>IGC Pharma INC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Puerto Rico</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
  </location_countries>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>December 29, 2020</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 11, 2021</study_first_posted>
  <last_update_submitted>September 14, 2022</last_update_submitted>
  <last_update_submitted_qc>September 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

